Insmed (INSM) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$1.1B

Revenue (quarter)

$425.5M

Revenue growth (year over year)

+296.11%

Gross profit (trailing twelve months)

$949.4M

Gross margin

83.46%

Net income (trailing twelve months)

−$875.3M

Net income (quarter)

−$13.2M

Net income growth (year over year)

+95.88%

Net margin

−76.94%

Return on equity

−87.22%

EPS (trailing twelve months)

−$4.12

Book value per share

$3.47

P/E (trailing twelve months)

—

Price to book

28.60

Debt to assets

63.97%

Payout ratio

—

Dividend yield

—

Company profile

Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

• Is Insmed (INSM) profitable?

  No. Insmed reported a net loss of $875.3M over the trailing twelve months.

• How much revenue does Insmed (INSM) make?

  Insmed generated $1.1B in revenue over the trailing twelve months, up 296.11% year over year.

• How do I buy stock in Insmed (INSM)?

  INSM trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.